• A case of recurrent erythema induratum of Bazin in a patient with myelodysplastic syndrome
• A comparison of WHO-5 and ICC classifications in a series of myeloid neoplasms, considerations for hematopathologists and molecular pathologists
• A growing panoply of options for patients with paroxysmal nocturnal hemoglobinuria
• A practical approach on the classifications of myeloid neoplasms and acute leukemia: WHO and ICC
• A stimulating advance in erythropoiesis for patients with myelodysplastic syndromes
• Acute Renal Thrombotic Microangiopathy Caused by Eltrombopag and Romiplostim in a Patient with Myelodysplastic Syndromes (MDS) and Underlying Antiphospholipid Syndrome
• Acute therapy-related myelodysplastic syndromes following capecitabine and oxaliplatin therapy in gastric malignant tumor: A case report
• All-trans retinoic acid in hematologic disorders: not just acute promyelocytic leukemia
• Allogeneic haematopoietic stem cell transplantation induced remission of periarteritis nodosa associated with azacytidine-refractory myelodysplastic syndrome
• Allogeneic hematopoietic stem cell transplantation in a patient with MonoMAC syndrome and hematopoietic dysplasia which was induced by GATA2 deficiency: a case report and literature review
• Alloimmunization in myelodysplastic syndrome is associated with higher healthcare costs, longer hospitalizations, and increased mortality
• AML, myelodysplasia related, with STAG2 and SRSF2 comutations with myelocyte arrest
• Analysis and summary of clinical characteristics of 289 patients with paroxysmal nocturnal hemoglobinuria in Zhejiang Province
• Analysis of the efficacy and prognostic factors of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome with blastomycosis and survival comparison of different subtypes after the WHO 2022 reclassification
• Application of m6A regulators to predict transformation from myelodysplastic syndrome to acute myeloid leukemia via machine learning
• Applications of Flow Cytometry in Diagnosis and Evaluation of Red Blood Cell Disorders
• Assessing the Relevance of Non-molecular Prognostic Systems for Myelodysplastic Syndrome in the Era of Next-Generation Sequencing
• Autoimmune Hemolytic Anemia Associated With Myelodysplastic Syndrome: A Case Report
• Causes and characteristics of pre-engraftment mortality after allogeneic hematopoietic stem cell transplantation
• Characteristics and outcomes of children, adolescent, and young adult patients with myelodysplastic neoplasms: A single-center retrospective analysis
• Characterization of second primary malignancies post CAR T-cell therapy: real-world insights from the two global pharmacovigilance databases of FAERS and VigiBase
• Chilblains as a non-specific skin eruption in a patient with myelodysplastic neoplasm
• Childhood myelodysplastic syndromes: Is cytoreductive therapy useful before allogeneic hematopoietic stem cell transplantation?
• Chronic Myelomonocytic Leukemia and Atypical Chronic Myeloid Leukemia: A National Analysis
• Chronic myelomonocytic leukemia with ring sideroblasts/SF3B1 mutation presents with low monocyte count and resembles myelodysplastic syndromes with-RS/SF3B1 mutation in terms of phenotype and prognosis
• Clinical efficacy of allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome-evolved acute myeloid leukemia
• Clinical features and prognosis of patients with myeloid neoplasms harboring t(7;11)(p15;p15) translocation: a single-center retrospective study
• Clinical features and prognostic factors of advanced myelodysplastic syndromes in children
• Clinicopathologic correlates and prognostic impact of lymphoid aggregates in patients with myelodysplastic syndromes
• Clonal hematopoiesis: malignant implications, extrahematologic manifestations, and management
• Complete Blood Counts and Research Parameters in the Detection of Myelodysplastic Syndromes
• Computing cell state discriminates the aberrant hematopoiesis and activated microenvironment in Myelodysplastic syndrome (MDS) through a single cell genomic study
• Consensus recommendations for optimising the diagnosis and treatment of paroxysmal nocturnal haemoglobinuria in Singapore
• Current challenges in conditioning regimens for MDS transplantation
• Current state and future prospects of CAR T-cell therapy for myeloid malignancies
• Detection and clinical application of red blood cell survival
• Detection of decreased granules in neutrophils by automated hematology analyzers XR-1000 and UniCel DxH 800
• Deubiquitinases at the interplay between hematopoietic stem cell aging and myelodysplastic transformation
• Diagnostic landscape of first-time cytometric screening for paroxysmal nocturnal hemoglobinuria in Poland in 2013-2022
• DIAPH1 mutations predict a favorable outcome for de novo MDS
• Dissecting Out a Rare Mutation, STAT: Features of STAT3-Mutant Myeloid Neoplasms
• Erythroferrone in focus: emerging perspectives in iron metabolism and hematopathologies
• Fatal posterior reversible encephalopathy syndrome after blood transfusion in a patient with myelodysplastic syndromes
• Fibrinogen-like 1: A hepatokine linking liver physiology to hematology
• Flow cytometric analysis of erythroid precursors and mutational signatures of lower risk myelodysplastic syndromes identify responders to erythroid stimulating agents
• Flow cytometry in the differential diagnosis of myelodysplastic neoplasm with low blasts and cytopenia of other causes
• GATA2 deficiency syndrome: A compensatory mechanism gone awry?
• Genomic structural variants analysis in leukemia by a novel cytogenetic technique: Optical genome mapping
• Imetelstat: First Approval
• Immature erythroblasts in pleural effusion: an initial presentation of acute erythroid leukemia in a patient with a history of MDS
• Improvements in hematologic markers and decreases in fatigue with pegcetacoplan for patients with paroxysmal nocturnal hemoglobinuria and mild or moderate anemia (hemoglobin ≥10 g/dL) who had received eculizumab or were naive to complement inhibitors
• Increased ferroptosis of erythrocytes is associated with myelodysplastic syndromes
• Infection stress and a driver mutation interact to promote transformation to hematological malignancies
• Influence of TP53 Gene Mutations and its Allelic Status in Myelodysplastic Syndromes with Isolated 5q Deletion
• Kidney involvement in myelodysplastic syndromes
• Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial
• Low Levels of Natural Killer Cell in Newly Diagnosed Myelodysplastic Syndromes Patients May Confer Poor Prognosis: A Retrospective Cohort Study
• Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial
• MDS patient registries - achievements and challenges
• Melphalan Dose in Combination with Fludarabine Affects GI Toxicity and GVHD after Allogeneic Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndromes
• Micro-transplantation in an elderly patient with very high risk MDS:A case report and literature review
• MicroRNA dysregulation and its impact on apoptosis-related signaling pathways in myelodysplastic syndrome
• MicroRNA dysregulation in myelodysplastic syndromes: implications for diagnosis, prognosis, and therapeutic response
• Molecular monitoring of MDS: Watch this space!
• Molecular monitoring of myelodysplastic neoplasm: Don't just watch this space, consider the patient's ancestry
• Molecular pathophysiology of germline mutations in acute myeloid leukemia
• Molecular Taxonomy of Myelodysplastic Syndromes and its Clinical Implications
• Myelodysplasia cutis and VEXAS syndrome initially diagnosed as histiocytoid Sweet syndrome: A diagnostic pitfall
• Myeloid sarcoma in JAK2-positive myelodysplastic neoplasms with fibrosis: a case report and literature review
• Next generation sequencing reveals the mutation landscape of Chinese MDS patients and the association between mutations and AML transformations
• Patient-reported outcomes and daily activity assessed with a digital wearable device in patients with paroxysmal nocturnal hemoglobinuria treated with ravulizumab: REVEAL, a prospective, observational study
• Patients' perspectives on oral decitabine/cedazuridine for the treatment of myelodysplastic syndromes/neoplasms
• Pharmacokinetics of Briquilimab as a Conditioning Agent for Hematopoietic Stem Cell Transplantation in Patients With Severe Combined Immunodeficiency, Myelodysplastic Syndrome, or Acute Myeloid Leukemia
• Phase 1 dose escalation study of the MDM2 inhibitor milademetan as monotherapy and in combination with azacitidine in patients with myeloid malignancies
• Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors
• Predicting which subsets of patients with myelodysplastic neoplasms are more likely to progress to overt chronic myelomonocytic leukemia
• Prognostic mutations identified by whole-exome sequencing and validation of the Molecular International Prognostic Scoring System in myelodysplastic syndromes after allogeneic haematopoietic stem cell transplantation
• Prospective genetic germline evaluation in a consecutive group of adult patients aged <60 years with myelodysplastic syndromes
• Quality of life considerations in myelodysplastic syndrome: not only fatigue
• Reclassification of Myelodysplastic Neoplasms According to the 2022 World Health Organization Classification and the 2022 International Consensus Classification Using Open-Source Data: Focus on SF3B1- and TP53-mutated Myelodysplastic Neoplasms
• Red blood cell alloimmunization in transfused patients with myelodysplastic syndromes: a retrospective study from northern China
• Resolution of extravascular hemolysis with oral iptacopan monotherapy in a patient with treatment experienced paroxysmal nocturnal hemoglobinuria (PNH)
• RIOK2 transcriptionally regulates TRiC and dyskerin complexes to prevent telomere shortening
• RSL3 enhances ROS-mediated cell apoptosis of myelodysplastic syndrome cells through MYB/Bcl-2 signaling pathway
• SBDS Gene Mutation Increases ROS Production and Causes DNA Damage as Well as Oxidation of Mitochondrial Membranes in the Murine Myeloid Cell Line 32Dcl3
• Screening of Myelodysplastic Syndromes Using Research Parameters of Complete Blood Count: Automated Detection of Dysplasia
• Severe pulmonary arterial hypertension in congenital sideroblastic anemia from PUS1 mutation - a case report
• Targeting the CD47/SIRPα pathway in malignancies: recent progress, difficulties and future perspectives
• The CRISPR-Cas System and Clinical Applications of CRISPR-Based Gene Editing in Hematology with a Focus on Inherited Germline Predisposition to Hematologic Malignancies
• The m(6)A methyltransferase METTL14 promotes cell proliferation via SETBP1-mediated activation of PI3K-AKT signaling pathway in myelodysplastic neoplasms
• The roles of phosphorylation of signaling proteins in the prognosis of acute myeloid leukemia
• This differentiation block will not stand, man: ivosidenib for MDS
• Thrombosis in PNH: largely gone, but not forgotten
• TRANSFORMATION OF MYELODYSPLASTIC SYNDROME INTO ACUTE MYELOBLASTIC LEUKEMIA (CLINICAL CASE)
• Treatment characteristics and outcomes in lower-risk, non-del(5q) myelodysplastic syndromes: findings from a medical record review in the USA, Canada and Europe
• Update on Recommendations for Surveillance for Children with Predisposition to Hematopoietic Malignancy
• Variation characteristics and clinical significance of <em>TP53</em> in patients with myeloid neoplasms
• Venetoclax with hypomethylating agents versus intensive chemotherapy in newly diagnosed acute myeloid leukemia with myelodysplasia related changes: A propensity score-matched analysis based on International Consensus Classification
• WHO/ICC Classification for Myelodysplastic Neoplasms/Syndromes Performs Better for Subtype Cytomorphological Diagnosis?
• WT1 gene mutations impact post-transplant relapse in myelodysplastic syndrome with excess blasts 2 patients